NASDAQ:KROS

Keros Therapeutics (KROS) Stock Price, News & Analysis

Keros Therapeutics logo
$11.85 -0.15 (-1.22%)
As of 01:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Keros Therapeutics Stock (NASDAQ:KROS)

Advanced

Key Stats

Today's Range
$11.37
▼
$12.13
50-Day Range
$9.17
▼
$12.00
52-Week Range
$8.98
▼
$22.55
Volume
132,029 shs
Average Volume
297,348 shs
Market Capitalization
$232.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00
Consensus Rating
Moderate Buy

Company Overview

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-β) protein family. Its research has centered on disorders involving blood-cell production and muscle function.

The company’s pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions. These programs are investigational and are not approved treatments.

Founded in 2015 and based in Lexington, Massachusetts, Keros conducts research and clinical development with the aim of serving patients in multiple markets. Cofounder Jasbir Seehra has served as the company’s chief executive officer.

AI Generated. May Contain Errors.

Keros Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

KROS MarketRank™: 
3.010224948875 of 5 stars

Keros Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 557th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Keros Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Keros Therapeutics has a consensus price target of $20.00, representing about 70.5% upside from its current price of $11.73.

  • Amount of Analyst Coverage

    Keros Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Keros Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($3.36) to ($5.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Keros Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Keros Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Keros Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.27% of the float of Keros Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Keros Therapeutics has a short interest ratio ("days to cover") of 7.06.
  • Change versus previous month

    Short interest in Keros Therapeutics has recently decreased by 4.45%, indicating that investor sentiment is improving.
  • Dividend Yield

    Keros Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Keros Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Keros Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Keros Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for KROS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Keros Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Keros Therapeutics' insider trading history.
Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KROS Stock News Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Keros Therapeutics launches $5M share buyback program
FY2026 EPS Forecast for Keros Therapeutics Lifted by Analyst
Keros Therapeutics (NASDAQ:KROS) Upgraded to Hold at Wall Street Zen
See More Headlines

KROS Stock Analysis - Frequently Asked Questions

Keros Therapeutics' stock was trading at $20.36 at the start of the year. Since then, KROS shares have decreased by 42.4% and is now trading at $11.73.

Keros Therapeutics, Inc. (NASDAQ:KROS) released its quarterly earnings data on Thursday, November, 5th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of ($0.96) by $1.66. The firm had revenue of $40.01 million for the quarter, compared to analysts' expectations of $14.76 million. Keros Therapeutics had a negative net margin of 256.60% and a negative trailing twelve-month return on equity of 21.85%.

Keros Therapeutics' board initiated a stock buyback program on Wednesday, September 9th 2026, which authorizes the company to repurchase $5 million in shares, according to EventVestor. This means that the company could repurchase up to 2.3% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board believes its stock is undervalued.

Keros Therapeutics (KROS) raised $90 million in an IPO on Wednesday, April 8th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Keros Therapeutics' top institutional shareholders include Nantahala Capital Management LLC (7.59%), State Street Corp (2.76%), Goldman Sachs Group Inc. (1.30%) and Empowered Funds LLC (0.67%). Insiders that own company stock include Carl L Gordon, Carl L Gordon, Annita Tanini, Lorena Raquel Lerner, Jean Jacques Bienaime, Charles W Newton, Julius Knowles, Alpna Seth, Nima Farzan, Pontifax Management 4 GP (20 and Adar1 Capital Management, Llc.
View institutional ownership trends
.

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Oracle (ORCL), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Broadcom (AVGO), Marvell Technology (MRVL) and Micron Technology (MU).

Company Calendar

Last Earnings
11/05/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KROS
CIK
1664710
Fax
N/A
Employees
92
Year Founded
2015

Price Target and Rating

High Price Target
$23.00
Low Price Target
$18.00
Potential Upside/Downside
+70.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$87.01 million
Net Margins
-256.60%
Pretax Margin
-153.25%
Return on Equity
-21.85%
Return on Assets
-19.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.14
Quick Ratio
18.14

Sales & Book Value

Annual Sales
$40.76 million
Price / Sales
5.65
Cash Flow
$4.69 per share
Price / Cash Flow
2.50
Book Value
$14.22 per share
Price / Book
0.82

Miscellaneous

Outstanding Shares
19,624,000
Free Float
17,151,000
Market Cap
$230.19 million
Optionable
Optionable
Beta
1.13

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:KROS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners